Showing results (181-190 of 258) with videos related to

Sort By:
Pageof 26
Molecular Cancer Therapeutics|June 24, 2004
Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cellsAndrea I Loaiza-Pérez, Susan Kenney, Jamie Boswell, et al.
Cold Spring Harbor Molecular Case Studies|October 8, 2020
Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repair-deficient tumorsNobuyuki Takahashi, Vinodh N Rajapakse, Lorinc Pongor, et al.
Nature Cell Biology|May 18, 2004
Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasivenessBrenda K Eustace, Takashi Sakurai, Jean K Stewart, et al.
BMC Biology|January 29, 2020
The mitochondrial HSP90 paralog TRAP1 forms an OXPHOS-regulated tetramer and is involved in mitochondrial metabolic homeostasisAbhinav Joshi, Li Dai, Yanxin Liu, et al.
The Oncologist|June 9, 2020
A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast CancerMargaret E Gatti-Mays, Fatima H Karzai, Sanaz N Soltani, et al.
The Journal of Biological Chemistry|December 18, 2001
Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cellsSeok Hee Park, Sae Ra Lee, Byung Chul Kim, et al.
Cancer Research|April 17, 2008
DNA methyltransferase 1 and 3B activate BAG-1 expression via recruitment of CTCFL/BORIS and modulation of promoter histone methylationLunching Sun, Lei Huang, Phuongmai Nguyen, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 26, 2022
Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell CarcinomaRoma Pahwa, Janhavi Dubhashi, Anand Singh, et al.
Oncology Letters|September 14, 2019
Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild-type disease during the early disease courseJung-Min Lee, Dana-Adriana Botesteanu, Yusuke Tomita, et al.
British Journal of Cancer|June 25, 2019
RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancerDaniel Morgensztern, Michal Rose, Saiama N Waqar, et al.
Pageof 26